30 Jan 2012 VGX-100 Identified as Potential New Therapy for Improving Corneal Graft Survival
30 Jan 2012 biOasis Advances its Herceptin(R) BT2111 Program
29 Jan 2012 Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source
29 Jan 2012 Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell Lymphomas
29 Jan 2012 Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
26 Jan 2012 ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
25 Jan 2012 Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN
24 Jan 2012 Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer’s Disease
23 Jan 2012 ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer Society
21 Jan 2012 Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
21 Jan 2012 Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer
21 Jan 2012 FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor
18 Jan 2012 InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting Complement Driven Inflammation
13 Jan 2012 Seattle Genetics Announces Updates to ADCETRIS™ Prescribing Information
13 Jan 2012 Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
12 Jan 2012 Three Adimab Antibodies Enter Human Clinical Trials
09 Jan 2012 Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study
09 Jan 2012 Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
09 Jan 2012 Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial
09 Jan 2012 Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological Disorder
02 Jan 2012 Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott
30 Dec 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer
29 Dec 2011 Peregrine Provides Update on HCV Clinical Program
28 Dec 2011 Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia
21 Dec 2011 XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up